Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.41 |
| ▸ | PGR | P06401 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27433477 | 0.84 | PDE3B (0.44) | MMP12PDE3BPDE3ANR3C2NR3C1 | |
| SCHEMBL4102430 | 0.80 | PARP1 (0.44) | MMP12PDE3BPDE3ANR3C2NR3C1 | |
| SCHEMBL20278370 | 0.80 | PDE3B (0.55) | MMP12PDE3BPDE3ANR3C2NR3C1 | |
| SCHEMBL4290482 | 0.77 | IL4I1 (0.44) | MMP12PDE3BPDE3ANR3C2NR3C1 | |
| SCHEMBL8082246 | 0.75 | PGR (0.46) | MMP12PDE3BPDE3ANR3C2NR3C1 | |
| SCHEMBL31170800 | 0.75 | CES1 (0.41) | MMP12NR3C2NR3C1PGRIL4I1 | |
| SCHEMBL7281657 | 0.74 | GAA (0.40) | MMP12PDE3BPDE3ANR3C2NR3C1 | |
| SCHEMBL3600619 | 0.73 | IL4I1 (0.44) | MMP12PDE3BPDE3ANR3C2NR3C1 | |
| SCHEMBL8236302 | 0.73 | IL4I1 (0.44) | MMP12PDE3BPDE3ANR3C2NR3C1 | |
| SCHEMBL24869557 | 0.73 | NR3C1 (0.43) | MMP12PDE3BPDE3ANR3C2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522906-B2 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20140221364-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8680115-B2 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20090239903-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-7576078-B2 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576100-B2 | Muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7550459-B2 | Neurodegenerative diseases, psychological disorders; e.g. 4-[3-(3a -Cyclopropylmethoxy-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4H-benzo[1.4]oxazin-3-one | ACADIA PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7307075-B2 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS INC. (US) | 2007-12-11 | — | — | US | disclosed |
| EP-1828176-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | Acadia Pharmaceuticals Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060199810-A1 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2006-09-07 | — | — | US | disclosed |
| US-20060199813-A1 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006068904-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| EP-1461318-B9 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARM INC (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050209226-A1 | Neurodegenerative diseases, psychological disorders; e.g. 4-[3-(3a -Cyclopropylmethoxy-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4H-benzo[1.4]oxazin-3-one | ACADIA PHARMACEUTICALS INC. | 2005-09-22 | — | — | US | disclosed |
| EP-1461318-B1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARM INC (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1461318-A2 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | Acadia Pharmaceuticals Inc. (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20030176418-A1 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003057672-A2 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199813-A1 | Tetrahydroquinoline analogues as muscarinic agonists | CHRM3, CHRM5, CHRM2 | MMP12 2473/4885PDE3B 255/4885PDE3A 254/4885 |
| US-20050209226-A1 | Neurodegenerative diseases, psychological disorders; e.g. 4-[3-(3a -Cyclopropylmethoxy-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4H-benzo[1.4]oxazin-3-one | CHRNA4, CHRNA2, CHRNA5 | MMP12 4290/4885PDE3B 619/4885PDE3A 618/4885 |
| US-20030176418-A1 | Tetrahydroquinoline analogues as muscarinic agonists | CHRM3, CHRM5, CHRM2 | MMP12 2473/4885PDE3B 255/4885PDE3A 254/4885 |
| US-20140221364-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | CHRM3, CHRM5, CHRM2 | MMP12 2473/4885PDE3B 255/4885PDE3A 254/4885 |
| US-20090239903-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | CHRM3, CHRM5, CHRM2 | MMP12 2473/4885PDE3B 255/4885PDE3A 254/4885 |
| US-20060199810-A1 | Muscarinic agonists | CHRM3, CHRM5, CHRM2 | MMP12 1811/4885PDE3B 327/4885PDE3A 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.